Ravi Cheruvu has joined the alternative investment team at PRS Group as Risk Manager.
Prior to joining PRS, Cheruvu was the Risk Manager at Paramount Biocapital, a
Ravi Cheruvu has joined the alternative investment team at PRS Group as Risk Manager.
Prior to joining PRS, Cheruvu was the Risk Manager at Paramount Biocapital, a biotech long/short equity hedge fund. Before Paramount, he was the Director of Research at Altgate Capital, where he was responsible for conducting due diligence on hedge funds.
Previously, Cheruvu also worked in the Firmwide Risk Department at Goldman Sachs, building risk models and developing asset allocation applications for various trading desks across the firm.
Cheruvu will head PRS Group’s risk management effort for its fund of hedge funds area as well as its convertible bond arbitrage program. In addition to developing customised risk management tools, he will lead initiatives to enhance client reporting for institutions and high net worth individuals to offer even better insight into their investments in PRS funds.
Mark Casa, Director of Investments for PRS Group, said, “To acquire the services of such an experienced and accomplished risk manager has been a long-term objective of the group. Ravi’s contributions will only add to the strength of the investment management team, both on the converts book and in the fund of funds business. It will also allow our senior fund of funds portfolio managers, Brian Pearl and Jerry Levin, the ability to focus exclusively on portfolio construction and manager searches.”
Background Note: PRS Group, which was founded in 1981, has been exclusively dedicated to hedge fund investing since 1987. Today, PRS Group manages over USD 1.5 billion in funds of hedge funds and convertible bond arbitrage for institutional and high net worth individual clients through proprietary funds, structured products and separate accounts.
Â
